OSCR
Oscar Health, Inc.
OSCR has the edge over RGEN overall, supported by stronger fundamentals and stronger modeled upside.
RGEN
Repligen Corporation
RGEN has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
RGEN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
RGEN's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
RGEN PE Valuation
RGEN has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over RGEN on the outlook, with more favorable profitability expectations.
RGEN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for RGEN, but weaker profitability.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the stronger earnings trend. Trailing diluted EPS is up 147% for OSCR versus RGEN up 38%.
RGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.43 | -16% |
| Q3 2022 | $2.90 | +38% |
| Q2 2022 | $2.77 | +55% |
| Q1 2022 | $2.53 | +74% |
| Q4 2021 | $2.24 | +102% |
| Q3 2021 | $2.10 | +156% |
| Q2 2021 | $1.79 | +209% |
| Q1 2021 | $1.45 | +222% |
| Q4 2020 | $1.11 | +152% |
RGEN's earnings per share have climbed steadily: $2.90 over the past year, up 38% from the year before, and higher year over year every quarter since late 2020.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over RGEN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over RGEN on profitability, with a higher operating margin.
RGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $209.3M | +11% |
| Q2 2026 | $204.1M | +12% |
| Q1 2026 | $194.3M | +15% |
| Q4 2025 | $197.9M | +18% |
| Q3 2025 | $188.8M | +22% |
| Q2 2025 | $182.4M | +15% |
| Q1 2025 | $169.2M | +10% |
| Q4 2024 | $167.5M | +0.6% |
RGEN's revenue has grown year over year for nine quarters in a row: $209M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -14% | -23 points |
| Q2 2026 | 6.8% | -0.8 points |
| Q1 2026 | 8.2% | +4.3 points |
| Q4 2025 | 9% | +31 points |
| Q3 2025 | 8.9% | +14 points |
| Q2 2025 | 7.6% | +4.2 points |
| Q1 2025 | 3.9% | +1.4 points |
| Q4 2024 | -22% | -28 points |
RGEN's operating margin was −14% last quarter, down 23 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over RGEN on cash flow, with more consistent year-over-year improvement.
RGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $38.2M | -12% |
| Q2 2026 | $27.4M | +28% |
| Q1 2026 | $23.6M | +106% |
| Q4 2025 | $17.6M | -48% |
| Q3 2025 | $43.4M | +2.5% |
| Q2 2025 | $21.5M | -42% |
| Q1 2025 | $11.4M | -69% |
| Q4 2024 | $33.6M | +87% |
RGEN generated $107M in free cash flow over the past year, down 3% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -80K shares |
| 1 year | -1.4% | -810K shares |
RGEN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over RGEN on leverage, with a lower net debt burden relative to earnings.
RGEN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.8x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | -2.7x | Net Cash |
| Q2 2025 | -14.0x | Net Cash |
| Q1 2025 | -17.8x | Net Cash |
| Q4 2024 | -21.9x | Net Cash |
RGEN has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
RGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.2 | Neutral |
| Stochastic | 48.9 | Neutral |
RGEN's weekly RSI is 53 (neutral) and its Stochastic is 49 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
RGEN PE vs Healthcare Sector
| Metric | RGEN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
RGEN has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over RGEN on trend strength, trading above more of its moving averages.
RGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $176.8 | 5.8% below |
| 20 week MA | $166.0 | 0.3% above |
| 50 week MA | $147.6 | 13% above |
| 100 week MA | $142.8 | 17% above |
| 200 week MA | $152.1 | 9.5% above |
RGEN has slipped below its 8-week average, but it's still above the other four, and 9.5% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over RGEN on returns for 2026, with the stronger performance.
RGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $92.2 | $195.7 | +112% |
| 2021 | $195.7 | $264.7 | +35% |
| 2022 | $264.7 | $167.5 | -37% |
| 2023 | $167.5 | $179.8 | +7.3% |
| 2024 | $179.8 | $145.5 | -19% |
| 2025 | $145.5 | $166.2 | +14% |
| 2026 YTD | $166.2 | $166.5 | +0.2% |
RGEN has finished higher in four of the last six years. It's roughly flat so far in 2026.